{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:28:17Z","timestamp":1786436897831,"version":"build-2736575974"},"reference-count":68,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Oliver Langenberg Physician-Scientist Training Program at Washington University School of Medicine"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32 DK007120"],"award-info":[{"award-number":["T32 DK007120"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Adrenocortical carcinoma (ACC) is a rare and often fatal malignancy currently only cured by surgery. Large-scale studies have failed to capture benign to malignant transition events, and patients often present with metastatic disease. These observations suggest ACC develops rapidly without a measurable precursor lesion, forming the basis of widely implemented adrenal incidentaloma guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to characterize the prevalence of antecedent adrenal nodules, quality of preoperative diagnostic workup, and the impact on survival for adults with ACC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed clinical data from 108 consecutive patients referred to a single tertiary academic medical center from 2000 to 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median follow-up was 86.7 months. Strikingly, 31.7% harbored antecedent nodules, indolent for a median 4.68 years before ACC presentation, and ultimately associated with a higher risk of death (adjusted hazard ratio [HR], 2.9; 95% CI, 1.39-6.0). Regarding preoperative evaluation, 46.4% were referred to endocrinology, associated with more complete hormonal assessment; 31.4% had adrenal biopsy, accompanied by increased risk of progression (adjusted HR, 2.53; 95% CI, 1.24-5.2) and death (adjusted HR, 2.22; 95% CI, 1.07-4.6). Patients with high-grade disease received more interventions; those who received mitotane and\/or locoregional therapies had improved survival (adjusted HR, 0.31; 95% CI, 0.14-0.71, and adjusted HR, 0.47; 95% CI, 0.23-0.98, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The unexpectedly high prevalence of indolent antecedent adrenal nodules suggests a prolonged, clinically premalignant phase in a subset of ACC. Initial diagnostic evaluation was often incomplete or inappropriately invasive, compromising the preoperative window and patient survival. These findings challenge current surveillance paradigms, revealing an extended but vulnerable window for surgical cure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvag161","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:45:46Z","timestamp":1784115946000},"source":"Crossref","is-referenced-by-count":0,"title":["Frequent antecedent nodules and diagnostic gaps in adrenocortical carcinoma"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-9416","authenticated-orcid":false,"given":"Dipika R","family":"Mohan","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Weimholt","sequence":"additional","affiliation":[{"name":"Department of Pathology & Immunology, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Michael","family":"Brunt","sequence":"additional","affiliation":[{"name":"Department of Surgery, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]},{"name":"Siteman Cancer Center, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor C","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Surgery, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]},{"name":"Siteman Cancer Center, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8984-3079","authenticated-orcid":false,"given":"Sina","family":"Jasim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]},{"name":"Siteman Cancer Center, Washington University School of Medicine , St. Louis, MO 63110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"6","key":"2026081103370434100_bvag161-B1","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1210\/endrev\/bnac012","article-title":"Update on biology and genomics of adrenocortical carcinomas: rationale for emerging therapies","volume":"43","author":"Lerario","year":"2022","journal-title":"Endocr Rev"},{"issue":"11","key":"2026081103370434100_bvag161-B2","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"2026081103370434100_bvag161-B3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1245\/s10434-015-4803-x","article-title":"Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes","volume":"23","author":"Margonis","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2026081103370434100_bvag161-B4","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026081103370434100_bvag161-B5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.surg.2018.04.068","article-title":"Longitudinal patterns of recurrence in patients with adrenocortical carcinoma","volume":"165","author":"Glenn","year":"2019","journal-title":"Surgery"},{"issue":"10","key":"2026081103370434100_bvag161-B6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"2026081103370434100_bvag161-B7","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"issue":"23","key":"2026081103370434100_bvag161-B8","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2026081103370434100_bvag161-B9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026081103370434100_bvag161-B10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(24)00095-0","article-title":"Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial","volume":"25","author":"Campbell","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026081103370434100_bvag161-B11","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026081103370434100_bvag161-B12","doi-asserted-by":"crossref","first-page":"10371","DOI":"10.1038\/s41467-024-54661-9","article-title":"Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"2026081103370434100_bvag161-B13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1210\/clinem\/dgab865","article-title":"Cytoreductive surgery of the primary tumor in metastatic adrenocortical carcinoma: impact on patients\u2019 survival","volume":"107","author":"Srougi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026081103370434100_bvag161-B14","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1210\/jc.2019-00029","article-title":"Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma","volume":"104","author":"Gharzai","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026081103370434100_bvag161-B15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41416-022-02082-0","article-title":"Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma","volume":"128","author":"Kimpel","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"2026081103370434100_bvag161-B16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040706","article-title":"The value of local therapies in advanced adrenocortical carcinoma","volume":"16","author":"Kimpel","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026081103370434100_bvag161-B17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12020-025-04163-5","article-title":"Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma","volume":"88","author":"Ma","year":"2025","journal-title":"Endocrine"},{"issue":"10","key":"2026081103370434100_bvag161-B18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/oncolo\/oyae130","article-title":"Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma: a tertiary referral center retrospective study","volume":"29","author":"Chahla","year":"2024","journal-title":"Oncologist"},{"issue":"11","key":"2026081103370434100_bvag161-B19","doi-asserted-by":"crossref","first-page":"e4698","DOI":"10.1210\/clinem\/dgab449","article-title":"Combination of mitotane and locoregional treatments in low-volume metastatic adrenocortical carcinoma","volume":"106","author":"Boil\u00e8ve","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026081103370434100_bvag161-B20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/clinem\/dgac046","article-title":"Temporal trends in outcomes in patients with adrenocortical carcinoma: a multidisciplinary referral-center experience","volume":"107","author":"Daher","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026081103370434100_bvag161-B21","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European network for the study of adrenal tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2026081103370434100_bvag161-B22","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1210\/clinem\/dgab512","article-title":"Approach to the patient with adrenal incidentaloma","volume":"106","author":"Bancos","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026081103370434100_bvag161-B23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.surg.2007.07.013","article-title":"Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous","volume":"142","author":"Quayle","year":"2007","journal-title":"Surgery"},{"issue":"1","key":"2026081103370434100_bvag161-B24","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.23.29826","article-title":"Adrenal mass biopsy in patients without extraadrenal primary malignancy: a multicenter study","volume":"222","author":"Krishna","year":"2024","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"2026081103370434100_bvag161-B25","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0354","article-title":"Risk of complications after core needle biopsy in pheochromocytoma\/paraganglioma","volume":"30","author":"Zhang","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026081103370434100_bvag161-B26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archsurg.2009.59","article-title":"Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience","volume":"144","author":"Mazzaglia","year":"2009","journal-title":"Arch Surg"},{"issue":"2","key":"2026081103370434100_bvag161-B27","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/EJE-16-0297","article-title":"DIAGNOSIS OF ENDOCRINE DISEASE: the diagnostic performance of adrenal biopsy: a systematic review and meta-analysis","volume":"175","author":"Bancos","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026081103370434100_bvag161-B28","doi-asserted-by":"crossref","first-page":"K7","DOI":"10.1530\/EO-21-0031","article-title":"Adrenocortical cancer recurrence following initial transcutaneous biopsy: a rare demonstration of needle tract seeding","volume":"1","author":"Younes","year":"2021","journal-title":"Endocr Oncol"},{"issue":"4","key":"2026081103370434100_bvag161-B29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"2026081103370434100_bvag161-B30","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr Pract"},{"issue":"5","key":"2026081103370434100_bvag161-B31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026081103370434100_bvag161-B32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12020-020-02361-x","article-title":"The impact of adrenal tumor multidisciplinary team meetings on clinical outcomes","volume":"69","author":"Fukuoka","year":"2020","journal-title":"Endocrine"},{"issue":"10","key":"2026081103370434100_bvag161-B33","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","article-title":"American association of endocrine surgeons guidelines for adrenalectomy: executive summary","volume":"157","author":"Yip","year":"2022","journal-title":"JAMA Surg"},{"issue":"3","key":"2026081103370434100_bvag161-B34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.diabres.2006.09.037","article-title":"Awareness of pathophysiological concepts of type 2 diabetes: a survey in 847 physicians","volume":"76","author":"Busse","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"2026081103370434100_bvag161-B35","doi-asserted-by":"crossref","first-page":"e2459","DOI":"10.1210\/clinem\/dgac087","article-title":"Driving factors to pursue endocrinology training fellowship: empirical survey data and future strategies","volume":"107","author":"Tsai","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081103370434100_bvag161-B36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jss.2024.07.051","article-title":"Adrenal referral pattern: management of patients with an adrenal incidentaloma","volume":"302","author":"Allahwasaya","year":"2024","journal-title":"J Surg Res"},{"issue":"5","key":"2026081103370434100_bvag161-B37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","journal-title":"Cancer Cell"},{"issue":"11","key":"2026081103370434100_bvag161-B38","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-18-2693","article-title":"Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma","volume":"25","author":"Mohan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2026081103370434100_bvag161-B39","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1158\/0008-5472.CAN-22-2712","article-title":"\u03b2-catenin-driven differentiation is a tissue-specific epigenetic vulnerability in adrenal cancer","volume":"83","author":"Mohan","year":"2023","journal-title":"Cancer Res"},{"key":"2026081103370434100_bvag161-B40","unstructured":"Mohan DR, Weimholt C, Brunt LM, Brown TC, Jasim S. Supplement. Figshare. 2026. 10.6084\/m9.figshare.32943728"},{"key":"2026081103370434100_bvag161-B41","volume-title":"R: A Language and Environment for Statistical Computing","author":"Team RC","year":"2022"},{"issue":"3","key":"2026081103370434100_bvag161-B42","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1210\/jc.2014-3282","article-title":"Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma","volume":"100","author":"Juhlin","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026081103370434100_bvag161-B43","first-page":"79","article-title":"Smoking and adrenal cancer mortality among United States veterans","volume":"5","author":"Chow","year":"1996","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026081103370434100_bvag161-B44","article-title":"Smoking is associated with adrenal adenomas and adrenocortical carcinomas: a nationwide multicenter analysis","volume":"25","author":"Yousaf","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"2026081103370434100_bvag161-B45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1530\/EJE-20-0033","article-title":"High prevalence of smoking in patients with adrenal incidentalomas: causality or case selection?","volume":"183","author":"Olsen","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2026081103370434100_bvag161-B46","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.4213","article-title":"Trends in US adult smoking prevalence, 2011 to 2022","volume":"4","author":"Meza","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"10","key":"2026081103370434100_bvag161-B47","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1210\/clinem\/dgad199","article-title":"New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study","volume":"108","author":"Puglisi","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026081103370434100_bvag161-B48","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-8587(20)30314-4","article-title":"Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study","volume":"8","author":"Ebbehoj","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026081103370434100_bvag161-B49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7326\/M18-3630","article-title":"Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis","volume":"171","author":"Elhassan","year":"2019","journal-title":"Ann Intern Med"},{"issue":"8","key":"2026081103370434100_bvag161-B50","article-title":"Transformation of a benign adrenocortical adenoma to a metastatic adrenocortical carcinoma is rare but it happens","volume":"2","author":"Angelousi","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"4","key":"2026081103370434100_bvag161-B51","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad170","article-title":"Clinical and pathological predictors of death for adrenocortical carcinoma","volume":"8","author":"Pato","year":"2024","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026081103370434100_bvag161-B52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.surg.2023.04.070","article-title":"The effect of hormonal secretion on survival in adrenocortical carcinoma: a multi-center study","volume":"175","author":"Sada","year":"2024","journal-title":"Surgery"},{"issue":"2","key":"2026081103370434100_bvag161-B53","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma","volume":"99","author":"Else","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026081103370434100_bvag161-B54","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026081103370434100_bvag161-B55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1530\/EJE-18-0450","article-title":"Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis","volume":"179","author":"Vanbrabant","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1-2","key":"2026081103370434100_bvag161-B56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2013.10.028","article-title":"Genetics and epigenetics of adrenocortical tumors","volume":"386","author":"Lerario","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"2026081103370434100_bvag161-B57","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2026081103370434100_bvag161-B58","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assi\u00e9","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"2026081103370434100_bvag161-B59","doi-asserted-by":"crossref","first-page":"8860","DOI":"10.1038\/s41467-025-63912-2","article-title":"Impact of steroid differentiation on tumor microenvironment revealed by single-nucleus atlas of adrenal tumors","volume":"16","author":"Jouinot","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"2026081103370434100_bvag161-B60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000469","article-title":"Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma","volume":"8","author":"Landwehr","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2026081103370434100_bvag161-B61","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/clinem\/dgae109","article-title":"Expression and prognostic relevance of PD-1, PD-L1, and CTLA-4 immune checkpoints in adrenocortical carcinoma","volume":"109","author":"Landwehr","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026081103370434100_bvag161-B62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12672-015-0225-2","article-title":"Radiographic characteristics of adrenal masses preceding the diagnosis of adrenocortical cancer","volume":"6","author":"Nogueira","year":"2015","journal-title":"Horm Cancer"},{"issue":"2","key":"2026081103370434100_bvag161-B63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12020-015-0694-7","article-title":"Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis","volume":"51","author":"Ozsari","year":"2016","journal-title":"Endocrine"},{"issue":"31","key":"2026081103370434100_bvag161-B64","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1038\/onc.2017.54","article-title":"P53\/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model","volume":"36","author":"Batisse-Lignier","year":"2017","journal-title":"Oncogene"},{"issue":"30","key":"2026081103370434100_bvag161-B65","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1038\/s41388-020-1358-5","article-title":"Wnt\/\u03b2-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice","volume":"39","author":"Borges","year":"2020","journal-title":"Oncogene"},{"issue":"41","key":"2026081103370434100_bvag161-B66","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add0422","article-title":"Sexually dimorphic activation of innate antitumor immunity prevents adrenocortical carcinoma development","volume":"8","author":"Wilmouth","year":"2022","journal-title":"Sci Adv"},{"issue":"7","key":"2026081103370434100_bvag161-B67","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s43587-023-00420-2","article-title":"Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner","volume":"3","author":"Warde","year":"2023","journal-title":"Nat Aging"},{"issue":"10","key":"2026081103370434100_bvag161-B68","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1530\/ERC-21-0040","article-title":"Targeted genomic analysis of 364 adrenocortical carcinomas","volume":"28","author":"Pozdeyev","year":"2021","journal-title":"Endocr Relat Cancer"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvag161\/69019063\/bvag161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/9\/bvag161\/69019063\/bvag161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/9\/bvag161\/69019063\/bvag161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:37:19Z","timestamp":1786433839000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag161\/8735762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag161","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,16]]},"article-number":"bvag161"}}